Astria Therapeutics Inc. (ATXS)
NASDAQ: ATXS
· Real-Time Price · USD
6.00
0.78 (14.94%)
At close: Jun 06, 2025, 3:59 PM
5.70
-5.08%
After-hours: Jun 06, 2025, 05:06 PM EDT
Company Description
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States.
Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema.
The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021.
Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
Astria Therapeutics Inc.
| Country | United States |
| IPO Date | Jun 25, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 78 |
| CEO | Jill C. Milne Ph.D. |
Contact Details
Address: 100 High Street Boston, Massachusetts United States | |
| Website | https://www.astriatx.com |
Stock Details
| Ticker Symbol | ATXS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001454789 |
| CUSIP Number | 04635X102 |
| ISIN Number | US04635X1028 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jill C. Milne Ph.D. | Co-Founder, Chief Executive Officer, President & Director |
| Benjamin S. Harshbarger J.D. | Chief Legal Officer |
| Noah C. Clauser CPA | Chief Financial Officer & Treasurer |
| Andrea L. Matthews | Chief Business Officer |
| Andrew A. Komjathy | Chief Commercial Officer |
| Dr. Christopher J. Morabito M.D. | Chief Medical Officer |
| John Ruesch | Senior Vice President of Pharmaceutical Sciences & Technical Operations |
| Keri McGrail | Chief Human Resources Officer |
| Rafif Dagher | Senior Vice President and Head of Discovery, Nonclinical Development & Translational Research |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| May 13, 2025 | 10-Q | Quarterly Report |
| May 12, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Apr 28, 2025 | ARS | Filing |
| Apr 28, 2025 | DEFA14A | Filing |
| Apr 28, 2025 | DEF 14A | Filing |
| Mar 25, 2025 | 4 | Filing |
| Mar 25, 2025 | 4 | Filing |
| Mar 25, 2025 | 4 | Filing |
| Mar 25, 2025 | 4 | Filing |